Concord Biotech Ltd
NSE:CONCORDBIO
Gross Margin
Concord Biotech Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
IN |
C
|
Concord Biotech Ltd
NSE:CONCORDBIO
|
158.9B INR |
76%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
846.5B USD |
81%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
376B USD |
68%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
85%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
214.9B CHF |
74%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
189.9B CHF |
75%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
166.3B GBP |
82%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
215.4B USD |
79%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
68%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
138.3B USD |
74%
|
Concord Biotech Ltd
Glance View
Nestled in the vibrant landscape of the Indian pharmaceutical industry, Concord Biotech Ltd. has woven itself into the intricate fabric of global healthcare solutions. Founded in 2000, the company has carved a niche for itself by becoming a leading manufacturer of fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients). Its core strength lies in developing recombinant APIs and fermentation-based life-saving drugs, establishing a robust pipeline that caters to the therapeutic needs of oncology, immunology, and infectious diseases. Concord Biotech's state-of-the-art manufacturing facilities adhere to stringent international standards, including approvals from USFDA and EUGMP, enabling the company to establish a significant presence in markets across the globe. The company's revenue model thrives on the optimized production of high-demand biotech APIs, synergizing innovation with commercial viability. By partnering with global pharmaceutical giants, Concord Biotech boosts the formulation and development of finished dosage forms, leveraging its cutting-edge research and development capabilities. The firm taps into economies of scale via partnerships and strategic alliances, which allow it to competitively price its offerings while maintaining robust profit margins. Moreover, the company continually invests in expanding its product portfolio and production capacities, ensuring sustainable growth and a strong market position in the ever-evolving pharmaceutical landscape. Through a combination of technological prowess and market insight, Concord Biotech Ltd. paves its path as a cornerstone in the global pharmaceutical supply chain.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Concord Biotech Ltd's most recent financial statements, the company has Gross Margin of 75.6%.